0.70
-0.0628(-8.23%)
Currency In USD
| Previous Close | 0.76 |
| Open | 0.75 |
| Day High | 0.75 |
| Day Low | 0.7 |
| 52-Week High | 4.45 |
| 52-Week Low | 0.4 |
| Volume | 547,855 |
| Average Volume | 1.17M |
| Market Cap | 111.18M |
| PE | -0.71 |
| EPS | -0.98 |
| Moving Average 50 Days | 1.01 |
| Moving Average 200 Days | 1.01 |
| Change | -0.06 |
If you invested $1000 in Renovaro Biosciences Inc. (RENB) since IPO date, it would be worth $118.73 as of February 05, 2025 at a share price of $0.701. Whereas If you bought $1000 worth of Renovaro Biosciences Inc. (RENB) shares 5 years ago, it would be worth $150.97 as of February 05, 2025 at a share price of $0.701.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Renovaro Appoints Nathen Fuentes as Chief Financial Officer
GlobeNewswire Inc.
Jan 07, 2025 2:15 PM GMT
Senior Biotechnology and Specialty Healthcare Financial Executive Brings Extensive Experience in Leading Acquisition and Organic Growth Initiatives LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer dia
Renovaro to Acquire Predictive Oncology in All-Stock Transaction
GlobeNewswire Inc.
Jan 06, 2025 2:15 PM GMT
Acquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 pathology slides and decades of longitudinal drug response data Data provides a critical pathway to progress AI using the high-spee
Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV
GlobeNewswire Inc.
Dec 30, 2024 2:00 PM GMT
Current Renovaro Chairman to Lead Subsidiary’s Development Program and Commercialization LOS ANGELES and AMSTERDAM, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artifici